Jubilant Pharmova
Current Price
₹883
1 Year At A Glance - ₹10,000 invested a year ago would be worth ₹8,553 today
1Y Return
-14.91%
Trend
Bearish ↘
Vs NIFTY
Behind NIFTY ✗
Curious how ₹10,000 would have grown?
Explore returns, wealth creation, benchmark performance and similar stocks across different time periods.
Last 7 Sessions
Weekly Price Action
Fri, 21 Aug
₹880
Mon, 24 Aug
₹903
▲ 2.54%
Tue, 25 Aug
₹897
▼ 0.67%
Wed, 26 Aug
₹887
▼ 1.03%
Thu, 27 Aug
₹879
▼ 0.98%
Fri, 28 Aug
₹883
▲ 0.45%
Weekly Movement
Bullish ↗
Historical Performance
Price Evolution
Explore how the stock price evolved across different investment horizons.
Selected Period
1 Month
Return
Started At
₹935.15
Current Price
₹882.65
Every Start Date
What JUBLPHARMA returned depending on when you bought
A single return figure is one start date out of hundreds. These are every 5 and 10-year stretch JUBLPHARMA has been through, each beginning a month after the last.
5-year holding periods
181 of them. Median 11.0% a year, worst -25.1%, best 60.1%.
67.4% of them ended in profit.
10-year holding periods
121 of them. Median 13.8% a year, worst -0.9%, best 29.8%.
99.2% of them ended in profit.
Analysis Period
Explore Different Time Horizons
Switch between periods to see how returns, benchmark performance and peer comparisons change over time.
Investment Journey
How ₹10,000 Changed Over 20 Years
This simulation shows how long-term investors experienced wealth creation through market movements and compounding.
Final Portfolio Value
₹76,840
+668.4%
Invested Amount
₹10,000
Profit / Loss
+₹66,840
CAGR
+10.7%
Benchmark Comparison
₹10,000 Investment Comparison (20 Years)
Compare how the same ₹10,000 investment would have performed in this stock versus NIFTY50.
₹10,000 In This Stock
₹76,840
10.7% CAGR
₹10,000 In NIFTY50
₹58,994
9.3% CAGR
Wealth Difference
+30.3%
This stock created more wealth than investing in NIFTY50 over the selected period.
Sector Discovery
Top 20Y Sector Performers
Compare this stock with other wealth creators in the same sector.
Ajanta Pharmaceuticals
Return
+68683.19%
Torrent Pharmaceuticals
Return
+14154.30%
Divi's Laboratories
Return
+11925.52%
Granules India
Return
+9215.88%
Ipca Laboratories
Return
+6073.80%
NATCO Pharma
Return
+4483.56%
Aurobindo Pharma
Return
+2883.65%
Glenmark Pharmaceuticals
Return
+2872.10%
Sun Pharmaceutical Industries
Return
+2615.73%
Lupin
Return
+2313.79%
Sector Discovery
Stocks With Similar 20Y CAGR
Discover stocks that generated returns similar to this company.
Hindalco Industries
Return
+671.41%
Jindal Stainless
Return
+658.92%
Bata India
Return
+694.29%
Bank of Baroda
Return
+639.38%
Infosys
Return
+709.74%
The Ramco Cements
Return
+615.93%
ITC
Return
+724.55%
Glaxosmithkline Pharmaceuticals
Return
+728.73%
Nifty 500
Return
+738.26%
Tata Steel
Return
+604.02%
Stock DNA
How this stock actually behaved
Four measurements taken from the same 20 years of price history shown above — how fast it grew, how often it rose, how far it fell, and how it fared against the index. Each one is stated with the number behind it so you can check the working.
Overall
The plain average of the 4 measurements below. It describes what already happened. It is not a rating, a recommendation, or a forecast.
10.7% a year
Compounded at 10.7% annually over 20 years. The scale reaches 10 at 25% a year.
9 of 20 years up
Finished higher than the previous year in 9 of 20 years. The score is that ratio, nothing else.
−65.3% worst fall
Fell 65.3% from a previous year-end peak at its worst. Measured on year-end values, so deeper falls within a year are not captured.
+1.5pp a year
Beat the NIFTY 50 by 1.5 percentage points a year over 20 years. A score of 5 means it matched the index.
Every scale used here is published on our Methodology page.
Explore JUBLPHARMA Further
Go deeper on Jubilant Pharmova Ltd. — year-by-year returns, head-to-head comparisons, and how the whole sector performed.
Invest Monthly
- JUBLPHARMA SIP returns→
- JUBLPHARMA dividend history→
- JUBLPHARMA rolling returns→
- JUBLPHARMA all-time high→
What ₹10,000 a month into JUBLPHARMA would have become, how much of its return came from dividends, every holding period on record, and how far it sits below its all-time high.
Investor Questions
Things Investors Usually Ask About JUBLPHARMA
Quick answers to the most important questions investors consider before researching a stock.
Jubilant Pharmova Ltd. compounded at approximately 10.7% a year over the last 20 years. CAGR is the steady annual rate that would produce the same result, so it can be compared directly against other stocks and against the index.
₹10,000 invested in Jubilant Pharmova Ltd. would have grown to approximately ₹76,840 over the analysed period, based on historical adjusted closing prices. That is a total return — dividends and stock splits are included — before brokerage and taxes.
We hold 20 years of usable daily price history for Jubilant Pharmova Ltd., and every figure on this page is measured within that window. Usable history can be shorter than the time a company has been listed: where our price source has a break we cannot verify — an unadjusted split, or a stretch of repeated closes — we cut the series back to after that break rather than publish a long-run number we do not trust.
The two are measured on different price series, on purpose. Returns and wealth figures use closing prices adjusted for dividends and splits, so dividends count as reinvested. The prices displayed are the raw quoted closes, so you can check them against your broker or the exchange. For a dividend payer the end price divided by the start price will therefore not reproduce the return figure — that gap is the dividends.
Past performance does not predict future returns. Valuation, revenue and earnings growth, balance-sheet quality, sector outlook and competitive position all matter, and none of them are visible in a return figure. ReturnScreener publishes the historical record only — it does not evaluate any of those things.
How This Is Calculated
Reading these figures properly
Total return, before costs
Returns and wealth figures use closing prices adjusted for dividends and splits, so dividends are treated as reinvested. Demergers are not credited, and brokerage and taxes are not modelled. The prices shown alongside are the raw quoted closes, so they can be checked against your broker.
The start date decides the answer
Every CAGR here is measured between two dates. A different starting year can move it substantially, which is why this page reports several horizons rather than one headline number.
Survivors only
Jubilant Pharmova Ltd.is in today's Nifty 500 universe. Companies that delisted or collapsed are not on this site at all — a bias worth holding in mind when reading any long-run historical figure.
Measured on data to 31 Aug 2026. Full definitions are on our methodology page.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. Past performance does not guarantee future returns. See our methodology and disclaimer.